Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.

Mamelak AN, Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB, Fiveash JB, Shen S, Khazaeli MB, Colcher D, Liu A, Osman M, Guthrie B, Schade-Bijur S, Hablitz DM, Alvarez VL, Gonda MA.

J Clin Oncol. 2006 Aug 1;24(22):3644-50.

PMID:
16877732
2.

Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.

Buchsbaum DJ, Khazaeli MB, Axworthy DB, Schultz J, Chaudhuri TR, Zinn KR, Carpenter M, LoBuglio AF.

Clin Cancer Res. 2005 Nov 15;11(22):8180-5.

3.

Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.

Rogers BE, Roberson PL, Shen S, Khazaeli MB, Carpenter M, Yokoyama S, Brechbiel MW, LoBuglio AF, Buchsbaum DJ.

Cancer Biother Radiopharm. 2005 Oct;20(5):502-13. Erratum in: Cancer Biother Radiopharm. 2005 Dec;20(6):671.

4.

Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.

Forero A, Meredith RF, Khazaeli MB, Shen S, Grizzle WE, Carey D, Busby E, LoBuglio AF, Robert F.

Cancer Biother Radiopharm. 2005 Oct;20(5):467-78.

PMID:
16248762
5.

Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.

Forero-Torres A, Shen S, Breitz H, Sims RB, Axworthy DB, Khazaeli MB, Chen KH, Percent I, Besh S, LoBuglio AF, Meredith RF.

Cancer Biother Radiopharm. 2005 Aug;20(4):379-90.

PMID:
16114986
6.

Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.

Shen S, Forero A, LoBuglio AF, Breitz H, Khazaeli MB, Fisher DR, Wang W, Meredith RF.

J Nucl Med. 2005 Apr;46(4):642-51.

7.

Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion protein.

Shen S, Meredith R, Duan J, Forero A, Breitz H, Khazaeli MB, Brezovich I, LoBuglio A.

Cancer Biother Radiopharm. 2005 Feb;20(1):110-8.

PMID:
15778590
8.

Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing mice.

Shen S, Khazaeli MB, Gillespie GY, Alvarez VL.

J Neurooncol. 2005 Jan;71(2):113-9.

PMID:
15690125
9.

Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.

Arnoletti JP, Buchsbaum DJ, Huang ZQ, Hawkins AE, Khazaeli MB, Kraus MH, Vickers SM.

J Gastrointest Surg. 2004 Dec;8(8):960-9; discussion 969-70.

PMID:
15585383
10.

ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.

de Bono JS, Tolcher AW, Forero A, Vanhove GF, Takimoto C, Bauer RJ, Hammond LA, Patnaik A, White ML, Shen S, Khazaeli MB, Rowinsky EK, LoBuglio AF.

Clin Cancer Res. 2004 Nov 15;10(22):7555-65.

11.

Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.

Safavy A, Georg GI, Vander Velde D, Raisch KP, Safavy K, Carpenter M, Wang W, Bonner JA, Khazaeli MB, Buchsbaum DJ.

Bioconjug Chem. 2004 Nov-Dec;15(6):1264-74.

PMID:
15546192
13.

Pilot study using a humanized CC49 monoclonal antibody (HuCC49DeltaCH2) to localize recurrent colorectal carcinoma.

Agnese DM, Abdessalam SF, Burak WE Jr, Arnold MW, Soble D, Hinkle GH, Young D, Khazaeli MB, Martin EW Jr.

Ann Surg Oncol. 2004 Feb;11(2):197-202.

PMID:
14761924
14.

A novel monoclonal antibody design for radioimmunotherapy.

Forero A, Meredith RF, Khazaeli MB, Carpenter DM, Shen S, Thornton J, Schlom J, LoBuglio AF.

Cancer Biother Radiopharm. 2003 Oct;18(5):751-9.

PMID:
14629823
15.

Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma.

Chhieng DC, Rodriguez-Burford C, Talley LI, Sviglin H, Stockard CR, Kleinberg MJ, Barnes MN, Partridge EE, Khazaeli MB, Grizzle WE.

Hum Pathol. 2003 Oct;34(10):1016-21.

PMID:
14608535
16.

Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy.

Meredith R, Shen S, Macey D, Khazaeli MB, Carey D, Robert F, LoBuglio A.

Cancer Biother Radiopharm. 2003 Jun;18(3):393-404. Erratum in: Cancer Biother Radiopharm. 2003 Aug;18(4):671.

PMID:
12954125
17.

Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy.

Shen S, Meredith RF, Duan J, Brezovich I, Khazaeli MB, LoBuglio AF.

Cancer Biother Radiopharm. 2003 Apr;18(2):209-15.

PMID:
12804046
18.

A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma.

Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, Needle M, Waksal H, LoBuglio AF.

Clin Cancer Res. 2003 Apr;9(4):1323-32.

19.

Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.

Safavy A, Bonner JA, Waksal HW, Buchsbaum DJ, Gillespie GY, Khazaeli MB, Arani R, Chen DT, Carpenter M, Raisch KP.

Bioconjug Chem. 2003 Mar-Apr;14(2):302-10.

PMID:
12643740
20.

A new monitoring method using solid sorbent media for evaluation of airborne cyclophosphamide and other antineoplastic agents.

Larson RR, Khazaeli MB, Dillon HK.

Appl Occup Environ Hyg. 2003 Feb;18(2):120-31.

PMID:
12519686
21.

Development of an HPLC method for simultaneous analysis of five antineoplastic agents.

Larson RR, Khazaeli MB, Dillon HK.

Appl Occup Environ Hyg. 2003 Feb;18(2):109-19.

PMID:
12519685
22.

A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.

Posey JA, Khazaeli MB, Bookman MA, Nowrouzi A, Grizzle WE, Thornton J, Carey DE, Lorenz JM, Sing AP, Siegall CB, LoBuglio AF, Saleh MN.

Clin Cancer Res. 2002 Oct;8(10):3092-9.

23.

A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.

Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, Grizzle WE, Shen S, Austin JM, Barnes MN, Carey D, Schlom J, LoBuglio AF.

Clin Cancer Res. 2002 Sep;8(9):2806-11.

24.

Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.

Shen S, Meredith RF, Duan J, Macey DJ, Khazaeli MB, Robert F, LoBuglio AF.

J Nucl Med. 2002 Sep;43(9):1245-53.

25.

Monitoring method for surface contamination caused by selected antineoplastic agents.

Larson RR, Khazaeli MB, Dillon HK.

Am J Health Syst Pharm. 2002 Feb 1;59(3):270-7.

PMID:
11862639
26.

Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.

Meredith RF, Alvarez RD, Partridge EE, Khazaeli MB, Lin CY, Macey DJ, Austin JM Jr, Kilgore LC, Grizzle WE, Schlom J, LoBuglio AF.

Cancer Biother Radiopharm. 2001 Aug;16(4):305-15.

PMID:
11603001
27.

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.

Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW.

J Clin Oncol. 2001 Jul 1;19(13):3234-43.

PMID:
11432891
28.

Expression of human endogenous retrovirus k envelope transcripts in human breast cancer.

Wang-Johanning F, Frost AR, Johanning GL, Khazaeli MB, LoBuglio AF, Shaw DR, Strong TV.

Clin Cancer Res. 2001 Jun;7(6):1553-60.

29.

A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer.

Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, LoBuglio AF.

Cancer Biother Radiopharm. 2001 Apr;16(2):125-32.

PMID:
11385959
30.

Quality control of radiolabeled monoclonal antibodies.

Khazaeli MB.

Cancer Biother Radiopharm. 2000 Dec;15(6):529-30. No abstract available.

PMID:
11190485
31.

Synthesis, rhenium-188 labeling and biodistribution studies of a phenolic ester derivative of trisuccin

Safavy A, Khazaeli MB, Mayo MS, Buchsbaum DJ.

Cancer Biother Radiopharm. 1997 Dec;12(6):375-84.

PMID:
10851491
32.

SEREX analysis for tumor antigen identification in a mouse model of adenocarcinoma.

Hampton TA, Conry RM, Khazaeli MB, Shaw DR, Curiel DT, LoBuglio AF, Strong TV.

Cancer Gene Ther. 2000 Mar;7(3):446-55.

33.

Improved synthesis of the bifunctional chelating agent 1,4,7,10-tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N',N'',N'''-tri s(acetic acid)cyclododecane (PA-DOTA).

Chappell LL, Rogers BE, Khazaeli MB, Mayo MS, Buchsbaum DJ, Brechbiel MW.

Bioorg Med Chem. 1999 Nov;7(11):2313-20.

PMID:
10632041
34.

Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis.

Spertini F, Leimgruber A, Morel B, Khazaeli MB, Yamamoto K, Dayer JM, Weisbart RH, Lee ML.

J Rheumatol. 1999 Dec;26(12):2602-8.

PMID:
10606369
35.

Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes.

Safavy A, Raisch KP, Khazaeli MB, Buchsbaum DJ, Bonner JA.

J Med Chem. 1999 Nov 18;42(23):4919-24.

PMID:
10579854
36.

Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.

Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3153s-3159s.

PMID:
10541357
37.

Targeting strategies for cancer radiotherapy.

Buchsbaum DJ, Rogers BE, Khazaeli MB, Mayo MS, Milenic DE, Kashmiri SV, Anderson CJ, Chappell LL, Brechbiel MW, Curiel DT.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3048s-3055s.

PMID:
10541342
38.

Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.

Safavy A, Khazaeli MB, Safavy K, Mayo MS, Buchsbaum DJ.

Clin Cancer Res. 1999 Oct;5(10 Suppl):2994s-3000s.

PMID:
10541333
39.

Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer.

Meredith RF, Khazaeli MB, Macey DJ, Grizzle WE, Mayo M, Schlom J, Russell CD, LoBuglio AF.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3254s-3258s.

PMID:
10541372
40.

Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration.

Conry RM, Khazaeli MB, Saleh MN, Allen KO, Barlow DL, Moore SE, Craig D, Arani RB, Schlom J, LoBuglio AF.

Clin Cancer Res. 1999 Sep;5(9):2330-7.

41.

Further studies on the protein conjugation of hydroxamic acid bifunctional chelating agents: group-specific conjugation at two different loci.

Safavy A, Khazaeli MB, Kirk M, Coward L, Buchsbaum DJ.

Bioconjug Chem. 1999 Jan-Feb;10(1):18-23.

PMID:
9893959
42.

Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen.

Conry RM, White SA, Fultz PN, Khazaeli MB, Strong TV, Allen KO, Barlow DL, Moore SE, Coan PN, Davis I, Curiel DT, LoBuglio AF.

Clin Cancer Res. 1998 Nov;4(11):2903-12.

43.

Use of chlorotoxin for targeting of primary brain tumors.

Soroceanu L, Gillespie Y, Khazaeli MB, Sontheimer H.

Cancer Res. 1998 Nov 1;58(21):4871-9.

45.

Synthesis of bombesin analogues for radiolabeling with rhenium-188.

Safavy A, Khazaeli MB, Qin H, Buchsbaum DJ.

Cancer. 1997 Dec 15;80(12 Suppl):2354-9.

PMID:
9406683
46.

Localization of iodine-125-mIP-Des-Met14-bombesin (7-13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer.

Rogers BE, Rosenfeld ME, Khazaeli MB, Mikheeva G, Stackhouse MA, Liu T, Curiel DT, Buchsbaum DJ.

J Nucl Med. 1997 Aug;38(8):1221-9.

47.

Adenoviral-mediated delivery of gastrin-releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo.

Rosenfeld ME, Rogers BE, Khazaeli MB, Mikheeva G, Raben D, Mayo MS, Curiel DT, Buchsbaum DJ.

Clin Cancer Res. 1997 Jul;3(7):1187-94.

48.

Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials.

Liu T, Meredith RF, Saleh MN, Wheeler RH, Khazaeli MB, Plott WE, Schlom J, LoBuglio AF.

Cancer Biother Radiopharm. 1997 Apr;12(2):79-87.

PMID:
10851451
49.

Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study.

Alvarez RD, Partridge EE, Khazaeli MB, Plott G, Austin M, Kilgore L, Russell CD, Liu T, Grizzle WE, Schlom J, LoBuglio AF, Meredith RF.

Gynecol Oncol. 1997 Apr;65(1):94-101.

PMID:
9103398
50.

Approaches to enhance cancer radiotherapy employing gene transfer methods.

Buchsbaum DJ, Raben D, Stackhouse MA, Khazaeli MB, Rogers BE, Rosenfeld ME, Liu T, Curiel DT.

Gene Ther. 1996 Dec;3(12):1042-68. Review.

PMID:
8986431

Supplemental Content

Loading ...
Support Center